Camp4 Therapeutics (CAMP) Free Cash Flow (2023 - 2026)
Camp4 Therapeutics recorded quarterly Free Cash Flow of -$11.0 million in Q1 2026, down 276.11% quarter-over-quarter from $6.2 million in Q4 2025, and up 23.0% year-over-year from -$8.9 million in Q1 2025.
Camp4 Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$11.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 23.0% year-over-year to -$11.0 million; the TTM figure through Mar 2026 stood at -$26.6 million (up 45.38% YoY), while the FY2025 annual figure was -$29.9 million, up 34.42% from the prior year.
- Free Cash Flow came in at -$11.0 million for Q1 2026 at Camp4 Therapeutics, down from $6.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $6.2 million in Q4 2025 to a low of -$14.3 million in Q1 2025.
- A 4-year average of -$9.8 million and a median of -$11.1 million in 2024 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 156.22% in 2025 and fell as far as 28.03% in 2025.
- Camp4 Therapeutics' Free Cash Flow stood at -$11.7 million in 2023, then climbed by 5.36% to -$11.1 million in 2024, then surged by 156.22% to $6.2 million in 2025, then tumbled by 276.11% to -$11.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$11.0 million, $6.2 million, and -$11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | -11.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.00 Mn |
| Mar 31, 2026 | -11.00 Mn |
| Dec 31, 2025 | 6.25 Mn |
| Dec 31, 2025 | 6.25 Mn |
| Sep 30, 2025 | -11.22 Mn |
| Sep 30, 2025 | -11.22 Mn |
| Jun 30, 2025 | -10.62 Mn |
| Jun 30, 2025 | -10.62 Mn |
| Mar 31, 2025 | -14.29 Mn |
| Mar 31, 2025 | -14.29 Mn |
| Dec 31, 2024 | -11.11 Mn |
| Dec 31, 2024 | -11.11 Mn |
| Sep 30, 2024 | -9.69 Mn |
| Sep 30, 2024 | -9.69 Mn |
| Jun 30, 2024 | -13.60 Mn |
| Jun 30, 2024 | -13.60 Mn |
| Mar 31, 2024 | -11.16 Mn |
| Mar 31, 2024 | -11.16 Mn |
| Dec 31, 2023 | -11.74 Mn |
| Dec 31, 2023 | -11.74 Mn |